Document Type: Original Article

Authors

Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: After intensified economic sanctions against Iran, decreased welfare of patients were more recognizable. The present study was aimed at identifying the challenges and stress level experienced by patients with multiple sclerosis (MS) regarding treatment and health care services in 2018-2019 after strengthening of economic sanctions against Iran.
Methods: A cross-sectional study was conducted on MS patients in Tehran, Iran. A structured questionnaire was designed to measure the main variables addressing the challenges and stress level of MS patients with respect to receiving care and treatment services.
Results: In total, 1039 MS patients were enrolled into the study. Among the patients who answered yes to the selected questions, 873 (85.8%) and 837 (86%) were concerned about medicine unavailability and supply and purchase of internationally branded medicine, respectively. Moreover, 671 (70.3%) subjects were concerned about replacing their medicines with cheaper alternatives due to financial problems and 427 (41.4%) were unwilling to continue their treatment due to the economic burden of MS. In total, 795 (82%) were concerned about the effectiveness of Iranian drugs in comparison with internationally branded drugs. Generally, 970 (93.53%) subjects had experienced increased current living costs and 711 had experienced (68.82%) reduced nutrition quality, which (OR: 2.68; 95% CI: 1.99, 3.60) was significantly higher among subjects who had an income of less than or equal to 250 US$ per month
Conclusion: The sanctions can impose greater stress and hardship on patients due to the unavailability and costs of medicines. Iran should manage health care quality and provide services to prevent the adverse effects of sanctions on MS patients and guarantee patients’ right to receive well-established medication and health services.

Keywords

  1. Singh PK, Travis P. Universal health coverage in the World Health Organization South-East Asia Region: How can we make it "business unusual"? WHO South East Asia J Public Health 2018; 7(1): 1-4.
  2. Rashidian A, Jahanmehr N, Jabbour S, Zaidi S, Soleymani F, Bigdeli M. Bibliographic review of research publications on access to and use of medicines in low-income and middle-income countries in the Eastern Mediterranean Region: Identifying the research gaps. BMJ Open 2013; 3(10): e003332.
  3. Aloosh M, Salavati A, Aloosh A. Economic sanctions threaten population health: The case of Iran. Public Health 2019; 169: 10-3.
  4. Sen K, Al-Faisal W, AlSaleh Y. Syria: Effects of conflict and sanctions on public health. J Public Health (Oxf) 2013; 35(2): 195-9.
  5. Gibbons E, Garfield R. The impact of economic sanctions on health and human rights in Haiti, 1991-1994. Am J Public Health 1999; 89(10): 1499-504.
  6. Duttagupta S, Yampolsky D, Chowdhury CA. Economic sanctions and market access for pharmaceuticals: Case studies with Russia, Cuba and Iran. Value in Health 2015; 18(7): A569.
  7. Petrescu IM. The Humanitarian impact of economic sanctions. Job Market Paper 2007; 1-25.
  8. Kokabisaghi F. Assessment of the effects of economic sanctions on iranians' right to health by using human rights impact assessment tool: A systematic review. Int J Health Policy Manag 2018; 7(5): 374-93.
  9. Garfield R. The impact of economic sanctions on health and well-being. London, UK: Overseas Development Institute; 1999.
  10. Asadi-Pooya AA, Tavana B, Tavana B, Emami M. Drug adherence of patients with epilepsy in Iran: the effects of the international economic sanctions. Acta Neurol Belg 2016; 116(2): 151-5.
  11. Farzanegan MR, Mohammadikhabbazan M, Sadeghi H. Effect of oil sanctions on the macroeconomic and household welfare in Iran: New evidence from a CGE model [Online]. [Cited 2015];
    Available from: URL: https://www.econstor.eu/handle/10419/109685
  12. Marzban H, Ostadzad A. The impact of economic sanctions on gross domestic product and social welfare for Iran: Generalized stochastic growth model. Iranian Journal of Economic Research 2015; 20(63): 37-69. [In Persian].
  13. Hosseini SA. Impact of sanctions on procurement of medicine and medical devices in Iran; A technical response. Arch Iran Med 2013; 16(12): 736-8.
  14. Mullane K. The increasing challenge of discovering asthma drugs. Biochem Pharmacol 2011; 82(6): 586-99.
  15. Wang H, Sun Q, Vitry A, Nguyen TA. Availability, price, and affordability of selected essential medicines for chronic diseases in 11 countries of the Asia pacific region: A secondary analysis. Asia Pac J Public Health 2017; 29(4): 268-77.
  16. Gholamzad M, Ebtekar M, Ardestani MS, Azimi M, Mahmodi Z, Mousavi MJ, et al. A comprehensive review on the treatment approaches of multiple sclerosis: Currently and in the future. Inflamm Res 2019; 68(1): 25-38.
  17. Zipp F, Oh J, Fragoso YD, Waubant E. Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. Nat Rev Neurol 2019; 15(8): 441-5.
  18. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet 2017; 389(10067): 403-76.
  19. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007; 85(4): 279-88.
  20. Davey HM, Barratt AL, Butow PN, Deeks JJ. A one-item question with a Likert or Visual Analog Scale adequately measured current anxiety. J Clin Epidemiol 2007; 60(4): 356-60.
  21. Kaye HS, Kang T, LaPlante MP. Mobility device use in the united states. Washington, DC: U.S. Department of Education, National Institute on Disability and Rehabilitation Research; 2000.
  22. Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis-a review of approved medications. Eur J Neurol 2016; 23(Suppl 1): 18-27.
  23. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet 2009; 373(9659): 240-9.
  24. Gyllensten H, Kavaliunas A, Murley C, Alexanderson K, Hillert J, Tinghog P, et al. Costs of illness progression for different multiple sclerosis phenotypes: A population-based study in Sweden. Mult Scler J Exp Transl Clin 2019; 5(2): 2055217319858383.
  25. Bloom DE, Cafiero ET, Jane-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S. The Global Economic Burden of Noncommunicable Diseases. Geneva, Switzerland: World Economic Forum; 2011.
  26. Zakrison TL, Muntaner C. US sanctions in Venezuela: Help, hindrance, or violation of human rights? Lancet 2019; 393(10191): 2586-7.
  27. Barry M. Effect of the U.S. embargo and economic decline on health in Cuba. Ann Intern Med 2000; 132(2): 151-4.
  28. Ahmadi AM, Meskarpour a. The public health effects of economic sanctions as a global concern in 21th century: Why the economic sanctions is a cruel strategy. Journal of Health Policy and Sustainable Health 2015; 2(1). [In Persian].
  29. Mucci N, Giorgi G, Roncaioli M, Fiz Perez J, Arcangeli G. The correlation between stress and economic crisis: A systematic review. Neuropsychiatr Dis Treat 2016; 12: 983-93.
  30. Jazairy I. Unilateral economic sanctions, international law, and human rights. Ethics Int Aff 2019; 33(3): 291-302.